Every day, wherever you live and whatever you're experiencing, we want you to know that Breastcancer.org is here for you. We're passionate about quickly providing you with reliable information as the COVID-19 pandemic evolves. Community members like you are the driving force behind all we do.
We’re committed to understanding the long-term impact of COVID-19 on breast cancer treatment and outcomes. We can’t do it without you. Please take our brief anonymous survey by May 31. Your answers will guide our programming, and help us to raise awareness about patient needs.
Our Breastcancer.org community knows how important it is to show support in many different ways. We want your ideas! What can you share or suggest to create a bright moment in someone's day? Post your answer with a photo on our Facebook page today.
We were honored to be part of a virtual event to share how Breastcancer.org has responded to the needs of our community. Through these continued collaborations with advocacy groups, industry, and patients, we will help as many people as possible.
The FDA approved Trodelvy to treat adults diagnosed with metastatic triple-negative breast cancer, and Tukysa in combination with Herceptin and Xeloda to treat metastatic HER2-positive breast cancer or locally advanced HER2-positive disease.
All donations to our COVID-19 RAPID RESPONSE FUND will be matched up to $100,000. To support Breastcancer.org programming and services, please make an online donation online today or text HELPBCO to 243725 to donate via your mobile device.
